Neuropathic Pain Market Outlook and Opportunities in Grooming Regions with Forecast 2030

Pune, India, March 2022, MRFR Press Release/- Market Research Future has published a Cooked Research Report on the Global Neuropathic Pain Market.

Market Highlights

The Global Neuropathic Pain Market is expected to reach USD 4.9 Billion by 2030 at 4.72% CAGR during the forecast period 2022-2030

Rising cases of cancer and technological advancements are driving the market growth. In addition, rising pipeline drugs by the companies for neuropathic pain is one of the major factors contributing to the growth of neuropathic pain.

Segment Analysis

Global Neuropathic Pain Market is segmented, based on Type, Into Peripheral Neuropathy (PN), entrapment neuropathy, trigeminal neuralgia, phantom limb pain (PLP), post herpetic neuralgia (PHN) and post-traumatic neuropathy. The global neuropathic pain market, by indication, is segmented as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, spinal stenosis, and others. The diabetic neuropathy segment is further categorized into painful diabetic peripheral neuropathy (PDPN), proximal neuropathy, autonomic neuropathy and focal neuropathy. The global neuropathic pain market on the basis of diagnosis is segmented into physical examination, imaging, and blood tests.  The global neuropathic pain market on the basis of treatment is segmented into medication and multimodal therapy. Furthermore, by medication, the market is segmented into NSAIDS, antidepressant drugs, anticonvulsants, and nerve blocks. The global neuropathic pain market, by distribution channel, is segmented into retail pharmacies & drug stores and online pharmacies. On the basis of end users, the global neuropathic pain market is segmented into hospitals, clinics, and research organizations.

Regional Analysis

Global Neuropathic Pain Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas held the largest market share of 36.24% of the neuropathic pain market in 2019. This share can be attributed to the technological development in the diagnosis of neuropathic pain and the high prevalence of neurological disorders in the region.

The European neuropathic pain market has been segmented into Western Europe and Eastern Europe. The Western Europe neuropathic pain market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The major players of these countries are involved in new product launches and acquisitions for the neuropathic pain market. The neuropathic pain market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The market growth in these countries is attributed to the large pool of patient population suffering from neurological pain and the growing aging population prone to such disorders. The Middle East & Africa neuropathic pain market has been divided into the Middle East and Africa.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Neuropathic Pain Market Research Report

Key Players

MRFR recognizes the following companies as the Key Players in the Global Neuropathic Pain Market— Abbott, GSK, Sanofi, Pfizer, Eli Lily, AstraZeneca, Johnson and Johnson, Biogen, Inc. Depomed, and Astellas.

Key Findings of the Study

• Global Neuropathic Pain Market is estimated to reach USD 4.9 Billion by 2030 at a CAGR of 4.72% during the assessment period of 2022 to 2030 


• The Americas accounted for the largest share of the global neuropathic pain market due to the presence of prominent players in the US, high uptake rate, and product clearances from regulatory authorities


• Based on type, the peripheral neuropathy segment accounted for the largest market share of 38.58% at a CAGR of 7.2% during the forecast period


• On the basis of indication, the diabetic neuropathy segment is expected to be the fastest-growing segment at a CAGR of 7.1% during the forecast period


• Based on diagnosis, the imaging segment is projected to register aCAGR of 6.9% during the forecast period


• On the basis of treatment, the medication segment accounted for a major market share of 77.3% in 2019 and is expected to exhibit a CAGR of 6.1% during the assessment period.


• Based on distribution channel, the retail pharmacies & drug stores segment accounted for a market share of 6.8% in 2019